Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial

du Bois A;Kristensen G;Ray-Coquard I;Reuss A;Pignata S;Colombo N;Denison U;Vergote I;Del Campo JM;Ottevanger P;Heubner M;Minarik T;Sevin E;de Gregorio N;Bidziński M;Pfisterer J;Malander S;Hilpert F;Mirza MR;Scambia G;Meier W;Nicoletto MO;Bjørge L;Lortholary A;Sailer MO;Merger M;Harter P;Scollo P

2016-01-01